A Study of BI 3810944 in Patients With Advanced Cancer
NCT07224425
·
clinicaltrials.gov ↗
PHASE1
Phase
RECRUITING
Status
69
Enrollment
INDUSTRY
Sponsor class
Conditions
Solid Tumours
Melanoma
Interventions
DRUG:
BI 3810944
Sponsor
Boehringer Ingelheim